Figure 2.

The amplitude of TGF-β-15 specific immune responses fluctuates over time. (A) Normalized counts at baseline were compared with counts after four series of treatment for patients with clinical benefit (left) and patients with progressive disease (right). Statistics made using Wilcoxon matched-pairs signed-rank test. (B) Representative pictures of baseline response and response after four series in a patient with clinical benefit (top), and of a response in a patient with progressive disease (bottom). (C) Normalized TGF-β-15 specific immune responses analyzed over time in three patients with clinical benefit. Normalization of spot counts performed as described previously. TGF-β, transforming growth factor-β.